Pharmaceutical Development

Porton Biopharma Appoints New Chair

Porton Biopharma Limited  is very pleased to announce the appointment of a new non-executive Chair for the Company, Barry Clare.  Barry is a pioneering healthcare business leader with extensive experience in the healthcare industry and an experienced non-executive director and company chair.   He is currently Deputy Chair of Manchester University Hospitals NHS Foundation Trust.

Barry has held a number of senior roles at leading international companies and has a proven track record in developing and implementing strategy in healthcare businesses, retail consumer products and in the financial sector.  Barry created Boots Healthcare International, the international ‘over the counter’ consumer healthcare business of the Boots Company PLC.

The appointment provides further exceptional industry experience for PBL as it enters its next phase of growth.

On his appointment to the role on 1st December 2018, Barry commented:

“I’m really looking forward to joining Porton Biopharma at this significant point in its evolution, helping the management team achieve the full potential of the company and continuing to supply high quality, important products for patients.”

Dr. Roger Hinton, Managing Director Porton Biopharma Ltd added:

“Having Barry as Chair will enhance the mix of skills and experience on our Board and support us in our growth. Following significant investment by our shareholder, we are looking forward to the increase in capacity of our facilities to better serve our patients’ needs and Barry will be key to this next phase.”

Duncan Selbie, Chief Executive Public Heath England added:

We are pleased that Barry with his wealth of commercial healthcare business experience has taken up this exciting opportunity and we are looking forward to working with him as PBL continues its growth.

I would like to thank Martin Hindle for his time at Porton Biopharma.  He was pivotal to the Company’s transformation out of Public Health England into a free-standing organisation and will continue to be a great advocate for the Company.”